Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec
Executive Summary
Fallout from GlaxoSmithKline's handling of Paxil pediatric studies may lead to increased pressure by Congress or FDA for greater disclosure, Schering-Plough Senior VP-Global Compliance & Business Practices Brenton Saunders said